<DOC>
	<DOCNO>NCT01811108</DOCNO>
	<brief_summary>Investigators propose ass , retrospectively ( 1/7/2009 ) prospectively ( 31/12/2013 , ) safety tolerability profile ( number participant adverse event ) standard chemotherapy anti-angiogenic agent bevacizumab ( Avastin ) first line treatment patient metastatic Colorectal Cancer without KRAS mutation . All treatment schedule go assess consider international guideline standard therapy patient metastatic Colorectal Cancer .</brief_summary>
	<brief_title>Assessment Clinical Practice Administration Chemotherapy Anti-angiogenic Agent ( Bevacizumab ) Colorectal Cancer</brief_title>
	<detailed_description>In addition investigator propose assess compliance patient treatment efficacy treatment . That mean percentage objective response , duration response , frequency curative liver resection administration treatment , progression free survival estimation overall survival</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Written inform consent Histologically confirm metastatic locally advanced nonoperable colorectal cancer No prior first line treatment metastatic colorectal cancer Age ≥18 year One measurable lesion ( ≥1cm diameter spiral CT scan ≥2cm conventional technique ) accord RECIST criterion ECOG performance status ≤2 Adequate haematological , renal hepatic function Urine protein &lt; 2+ ( dipstick ) Life expectancy ≥12 week Previous first line treatment metastatic colorectal cancer ( progression &gt; 6 month end adjuvant treatment ) Previous radiotherapy target lesion Patients brain metastasis and/or cancerous meningitis Metastatic infiltration &gt; 50 % liver parenchyma Presence history neoplasm except properly treat basal cell skin cancer situ cervical carcinoma Patients participate interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>mCRC</keyword>
	<keyword>KRAS mutation</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Anti-angiogenic agent</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>1st Line</keyword>
</DOC>